The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Enhanced multivalent vaccine responses using a novel vaccine vector system. Enhanced multivalent vaccine responses using a novel vaccine vector system. This project aims to develop a multicomponent vaccine system to deliver equal effectiveness against several disease targets in a single administration. New and innovative vaccine design strategies incorporating economical commercial production processes are urgently needed for new and existing human and animal health applications. A vaccine capab ....Enhanced multivalent vaccine responses using a novel vaccine vector system. Enhanced multivalent vaccine responses using a novel vaccine vector system. This project aims to develop a multicomponent vaccine system to deliver equal effectiveness against several disease targets in a single administration. New and innovative vaccine design strategies incorporating economical commercial production processes are urgently needed for new and existing human and animal health applications. A vaccine capable of targeting multiple diseases by a single injection is an obvious way to expedite future vaccine development and deployment. However, the recipient’s immune system can repress equivalent responses to these multicomponent vaccines. This project’s research is expected to address these problems, and underpin the future commercial development of this vaccine platform.Read moreRead less
Improving and manipulating the immune adjuvant properties of recombinant fowlpox vectors. Unbalanced immune responses may cause or worsen common and important diseases such as infections, allergies, cancers and autoimmunity. Interleukin-4 (IL-4) is the only immune active product or cytokine that safely skews an aberrant immune response to a healing type of response. Fowlpox viruses (FPV) provide safe and effective human vaccines. Engineering FPV to make both a relevant antigen and a cytokine is ....Improving and manipulating the immune adjuvant properties of recombinant fowlpox vectors. Unbalanced immune responses may cause or worsen common and important diseases such as infections, allergies, cancers and autoimmunity. Interleukin-4 (IL-4) is the only immune active product or cytokine that safely skews an aberrant immune response to a healing type of response. Fowlpox viruses (FPV) provide safe and effective human vaccines. Engineering FPV to make both a relevant antigen and a cytokine is proprietary technology. With our commercial partner and using experimental mice, we will test the concept that FPV making a model antigen and IL-4 initiate and/or maintain beneficial Type 2 responses. A successful outcome will guide clinical FPV-based vaccine development for the treatment of important human and veterinary diseases.Read moreRead less